[ad_1]
On Friday, Softox Solutions reports that the company has received the results of inhalation studies in mini pigs, which show very promising results with a view to further developing the company’s technology for the treatment of respiratory infections, including corona patients.
The company describes it as a “potential advance in the fight against the crown.”
The stock was up 54 percent after the announcement.
20 mill. in paper earnings on Friday
According to the company, the results indicate that “safe” concentrations have been found that do not damage the respiratory tract while having an antimicrobial effect.
– With our smooth and efficient technology, we now have the opportunity to plan the first human studies (phase I). Unlike many other treatments, our treatment is aimed directly at inactivating the coronavirus, says Softox CEO Geir Almås in the report.
The company is committed to hand and surface disinfectants that do not contain alcohol. In May, DN wrote that Apotek 1 had taken over the hand sanitizer and that the company had established production lines with a capacity of up to 45,000 bottles per day.
Almås is the second largest shareholder in Softox Soltuions through its private company Hermod Farms as. As a result of Friday’s price increase, this day alone has a paper profit of around NOK 20 million. Its shareholding now amounts to NOK 57 million.
It is also part of history that Softox stock was priced significantly higher earlier this year. At its highest in early May, the share price stood at NOK 112, compared to NOK 81 today.
– we are optimistic
The company has agreed to meet with the Danish Medicines Agency for advice on the future development path of the medicine.
– We are optimistic about achieving a faster path for patients with the so-called “fast track” recommendation, says Medical Director Glenn Gundersen at Softox.(Terms)Copyright Dagens Næringsliv AS and / or our suppliers. We would like you to share our cases via a link, which leads directly to our pages. Copying or other use of all or part of the content can only be done with written permission or as permitted by law. For more terms, see here.
